logo

IGC

IGC Pharma·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

IGC fundamentals

IGC Pharma (IGC) released its earnings on Nov 14, 2025: revenue was 190.00K (YoY -53.66%), missed estimates; EPS was -0.02 (YoY 0.00%), met estimates.
Revenue / YoY
190.00K
-53.66%
EPS / YoY
-0.02
0.00%
Report date
Nov 14, 2025
IGC Earnings Call Summary for Q2,2026
  • Key Drug Candidate Progress: IGC 81 reduces agitation in 2 weeks vs. 10 weeks for existing treatments.
  • Clinical Trial Expansion: 35 sites across U.S. and Canada with 50% enrollment.
  • Cost Management: Divested non-core assets to reduce expenses.
  • AI Innovation: MINT-AD predicts Alzheimer's risk using multimodal data.
  • 2026 Focus: Complete phase two trial and advance pipeline.
EPS
Revenue

Revenue & Expenses

IGC has released its 2026 Q2 earnings report, with revenue of 191.00K, reflecting a YoY change of -53.64%, and net profit of -1.82M, showing a YoY change of -6.06%. The Sankey diagram below clearly presents IGC's revenue sources and cost distribution.

Key Indicators

IGC Pharma (IGC) key financial stats and ratios, covering profitability, financial health, and leverage.
IGC Pharma (IGC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
IGC Pharma (IGC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
IGC Pharma (IGC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does IGC Pharma (IGC) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track IGC Pharma (IGC) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield